[go: up one dir, main page]

MX2023001157A - Anti-integrin beta7 antibody formulations and devices. - Google Patents

Anti-integrin beta7 antibody formulations and devices.

Info

Publication number
MX2023001157A
MX2023001157A MX2023001157A MX2023001157A MX2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A
Authority
MX
Mexico
Prior art keywords
devices
integrin beta7
beta7 antibody
antibody formulations
formulations
Prior art date
Application number
MX2023001157A
Other languages
Spanish (es)
Inventor
Jennifer Pulley
Meina Tao Tang
Swati Tole
Helen Tyrrell
Mariam Abouhossein
Hemanth Amarchinta
Audrey Boruvka
Han Ting Ding
Heather L Flores
Glen Scott Giese
Renato Ravanello
Wenhui Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023001157A publication Critical patent/MX2023001157A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulations comprising an anti-integrin beta7 antibody or an antigen-binding fragment thereof are provided, including pharmaceutical formulations. Also provided are article of manufactures comprising such formulations, and methods of using such formulations.
MX2023001157A 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices. MX2023001157A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
PCT/US2021/043690 WO2022026699A1 (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices

Publications (1)

Publication Number Publication Date
MX2023001157A true MX2023001157A (en) 2023-02-22

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001157A MX2023001157A (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices.

Country Status (11)

Country Link
EP (1) EP4188958A1 (en)
JP (1) JP2023536158A (en)
KR (1) KR20230041071A (en)
AR (1) AR123085A1 (en)
AU (1) AU2021316017A1 (en)
BR (1) BR112023001734A2 (en)
CA (1) CA3190109A1 (en)
IL (1) IL300133A (en)
MX (1) MX2023001157A (en)
TW (1) TW202222832A (en)
WO (1) WO2022026699A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60139944D1 (en) 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
HUE028441T2 (en) 2004-09-03 2016-12-28 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
US20100255508A1 (en) 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
CN108969761A (en) * 2011-05-02 2018-12-11 米伦纽姆医药公司 The preparation of 4 β of anti alpha, 7 antibody
USRE50441E1 (en) 2011-06-17 2025-05-27 Shl Medical Ag Injection device
BR112013032569B1 (en) 2011-06-17 2020-12-29 Shl Medical Ag injection device
KR102175688B1 (en) 2013-03-27 2020-11-06 제넨테크, 인크. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3262072A1 (en) * 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
JP2023536158A (en) 2023-08-23
CA3190109A1 (en) 2022-02-03
AU2021316017A1 (en) 2023-02-16
BR112023001734A2 (en) 2023-02-28
EP4188958A1 (en) 2023-06-07
WO2022026699A1 (en) 2022-02-03
TW202222832A (en) 2022-06-16
IL300133A (en) 2023-03-01
KR20230041071A (en) 2023-03-23
AR123085A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
MX2023014458A (en) Anti-ccr8 antibodies and uses thereof.
WO2020014460A8 (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
WO2021222935A3 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
MX2022004304A (en) Apoptosis-inducing agents.
EP4406554A3 (en) Anti-cd3 antibody formulations
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2020003939A (en) Mdm2 inhibitors and therapeutic methods using the same.
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MA53765B2 (en) Tubulysines et conjugués protéine-tubulysine
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2019186284A3 (en) Defined dose cannabis puck
MX2020008122A (en) Anti-pd-1 antibodies.
ZA202302392B (en) Antibodies against ilt2 and use thereof
WO2018136938A8 (en) Induction of protective immunity against antigens
MX2022015966A (en) Antibodies and methods for treating claudin-associated diseases.
PH12021551816A1 (en) Inactivated apxia, apxiia and apxiiia toxins
AU2017248276A1 (en) Methods of treating ocular conditions
WO2021118930A3 (en) Anti-pd-l1 antibody formulations
MX2018005226A (en) Anti-factor d antibody formulations.